Previous 10 | Next 10 |
MOUNTAIN VIEW, Calif., Sept. 30, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the first patient has been dosed in its Phase 1 clinical trial evaluating...
Calithera initiates Phase 2 trial for lung cancer treatment. Vertex receives FDA approval for cystic fibrosis treatment. IGM Biosciences makes a deal with AbCellera for antibody discovery. For further details see: Calithera Lung Cancer Trial, And Other News: The Good, Ba...
Immunome has filed proposed terms for a $30 million IPO. The firm is advancing antibody-based treatment candidates for cancer and the Covid-19 virus. IMNM is still at a preclinical stage of development, so the IPO is likely more suited to institutional investors. For further...
AbCellera and IGM Biosciences (IGMS) entered into a multi-year, multi-target strategic research collaboration and license agreement to facilitate the discovery and development of novel IgM antibodies.AbCellera will generate panels of antibodies for multiple therapeutic targets identified by I...
VANCOUVER, British Columbia and MOUNTAIN VIEW, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- AbCellera and IGM Biosciences, Inc. (Nasdaq: IGMS), announced today that they have entered into a multi-year, multi-target strategic research collaboration and license agreement to facilitate the disco...
Insider buying increased significantly last week. Notable Insider Buys: Public Storage, IGM Biosciences, Inc., Cassava Sciences, Inc., Intra-Cellular Therapies, Inc., Nikola Corporation. Notable Insider Sells: Scientific Games Corporation, Guardant Health, Inc., Antero Midstream C...
The following slide deck was published by IGM Biosciences, Inc. in conjunction with this Read more ...
IGM Biosciences ( IGMS , +15% ) is seeing another sharp gain, leaving technical levels well behind. More news on: IGM Biosciences, Inc., Healthcare stocks news, Merger & acquisition news, Read more ...
In a year dominated by the Covid crisis and the search for a treatment/vaccine, the last week has seen progress in the fight against cancer, and helped send the biotech sector surging. More news on: Gilead Sciences, Inc., Merck & Co., Inc., Immunomedics, Inc., , News on ETFs Read mo...
MOUNTAIN VIEW, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at four upcoming ...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 5.6% to $127.4 on volume of 368,729,821 shares Maxeon Solar Technologies Ltd. (MAXN) rose 14.2% to $0.2407 on volume of 294,399,898 shares Kazia Therapeutics Limited (KZIA) rose 85.6% to $1.24 on volume ...
2024-05-31 20:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-24 12:15:03 ET RBC Capital analyst issues UNDERPERFORM recommendation for IGMS on May 24, 2024 10:00AM ET. The previous analyst recommendation was Underperform. IGMS was trading at $10.01 at issue of the analyst recommendation. The overall analyst consensus : BUY...